Tassos Gianakakos
Algemeen Directeur bij MYOKARDIA, INC.
Vermogen: 112 536 $ op 30-04-2024
Actieve functies van Tassos Gianakakos
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MYOKARDIA, INC. | Algemeen Directeur | 01-10-2013 | - |
Directeur/Bestuurslid | 01-10-2013 | 17-11-2020 | |
President | 01-10-2013 | 17-11-2020 | |
LIANBIO | Directeur/Bestuurslid | 01-08-2020 | - |
Independent Dir/Board Member | 01-08-2020 | - | |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Directeur/Bestuurslid | - | - |
President | - | - |
Loopbaan van Tassos Gianakakos
Eerdere bekende functies van Tassos Gianakakos
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 01-09-2006 | 01-03-2013 |
MERCK & CO., INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-1997 | 01-01-1997 |
CODEXIS, INC. | President | 01-01-2001 | - |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - | - |
Opleiding van Tassos Gianakakos
Massachusetts Institute of Technology | Undergraduate Degree |
Northwestern University | Graduate Degree |
Harvard Business School | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 11 |
Operationeel
President | 3 |
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sectoraal
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
CODEXIS, INC. | Process Industries |
LIANBIO | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
- Beurs
- Insiders
- Tassos Gianakakos
- Ervaring